1

Anna Lönnroth (Deputy Head of Unit), Infectious Diseases, Health

Directorate, Research Directorate General, European Commission

Rome, 23 May 2007

EU Preparedness and Response

programs in Emerging and

Re-emerging Infectious Diseases

Who are we?

2

Directorate General

RESEARCH (DG RTD)Jose Maria SILVA RODRIGUEZ (DG)

Directorate

HEALTHOctavi QUINTANA TRIAS (director)

Unit

INFECTIOUS DISEASESBernard MULLIGAN (acting HoU)

Anna Lönnroth (deputy HoU)

EUROPEAN

COMMISSION

HIV / AIDS Malaria TB Neglected

Infectious

diseases

Antimicrobial drug

resistanceEmerging Epidemics

Cornelius Schmaltz

+ ~ 40 other

DGs (ex. SANCO)

+ 14 other

Directorates

(8 thematic + 7 horizontal)

+ 5 other Units: Coordination, Medical &

Public Health Research, Genomics & System

Biology, Health Biotechnology,

Administration & Finance

EDCTP

FP 7 (2007-2013)

3

3,27 5,36 6,613,12 14,96 17,5

68,3

0

10

20

30

40

50

60

70

80

1984-1987 1987-1991 1990-1994 1994-1998 1998-2002 2002-2006 2007-2013

€ Billion

Budgets of the EU Framework Programmes

Indicative breakdown (million €)

Total = 50.4 billion € over 7 years

Average 40% increase of yearly budget comparedto FP6, but heavily “tail-loaded“

ERC

4

5

Annual updates of Workprogrammes

1. Address major medical needs

2. Attract cutting-edge technologies

3. Foster translational research (“from genomics to public health”)

4. Involve industry, in particular SMEs

5. Involve International Cooperation PartnerCountries (ICPC), where relevant

Topics should:

First two calls for the Health theme

Specificities:

� not all areas will be open in each call

� ceilings for EU contribution (eligibility criteria!)

�S/M CP > 3 m€

�L IP 6-12 m€

�unless otherwise specified in the Workprogramme

� new provisions for ethics: no additional information to be asked

� page number limitation for proposals

�3 evaluation criteria:

�Scientific excellence

�Implementation

�Impact

6

Conditions for collaborative research

Collaborative projects must involve at least :

2 participants from 2 different Member States or Associated countries

2 partners from 2 different ICPCs

Specific international

cooperation actions (SICA )

ACP (African/ Caribbean/ Pacific)

ASIA

EASTERN EUROPE AND CENTRAL

ASIA (EECA)

LATIN AMERICA

MEDITERRANEAN PARTNER

COUNTRIES (MPC)

WESTERN BALKAN COUNTRIES

(WBC)

International

Co-operation

Partner

Countries

(ICPC)

7

EU research on infectious diseases

8

Activities in 4 fields:

1. Antimicrobial drug resistance

2. HIV/AIDS, malaria and tuberculosis

3. Emerging epidemics

4. Neglected (tropical) infectious diseases

Translational research in infectious diseases

9

EU Research on Emerging

Epidemics

5th and 6th Framework Programmes

�No dedicated area for Emerging Epidemics

�Funding mobilized in response to crises

�Dedicated call on SARS in 2003 (15 million €)

�Dedicated call on influenza in 2006 (28 million €)

�EU support since 2001 approx.15 million € / year

overall

7th Framework Programme

�Dedicated area on Emerging epidemics

�2007 call on flu / 2008 call on preparedness

�Future?

�Budget not earmarked – will be driven by need

Spring 2003 – outbreak in

South-East Asia and Canada

Immediate mobilization of 15 million € of

available resources – 7 projects funded

SARS 2003

10

11

Pandemic Influenza

2000 - 2007

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

EPIZONE 14 M€

HEALTHY POULTRY 1.2 M€

ESNIP 0.27 M€

AVIFLU 1.8 M€

FLUPAN 2.1 M€

ESNIP 2 0.3 M€

LAB-ON-SITE 1.5 M€

FLUAID 1.2 M€

FLUVACC 9.2 M€

VIZIER 13 M€

SARS/FLU VACCINE 1.6 M€

NOVAFLU 1.7 M€

VIRGIL 9 M€

Universal Vaccine 1.2 M€

MUCADJ 1M€

199919981997

2006, Key year for

EU Influenza Research:

• Early start, some

promising results

already available

• Critical mass of

ongoing collaborative

research projects

• New call for proposals

2006, Key year for

EU Influenza Research:

• Early start, some

promising results

already available

• Critical mass of

ongoing collaborative

research projects

• New call for proposals

Human Flu

Animal Flu

12

2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018200620052004

Human Flu

Animal Flu

FLUPOL 2 M€

FLUINNATE 1.4 M

PANFLUVAC 3.3 M€

Intranasal H5 2.7 M

FLUVAC 3.5 M€

EUROFLU 1.4 M€

NOVADUCK 1.4 M€

FLUTEST 1.5 M€

FLUPATH 1.9 M€

New Flubird 1.9 M€

FLUTEST 1.5 M€

FLURESIST 0.9 M€

FLU-LAB-NET 0.9M€

FLUTRAIN 1.8 M€

AIV VAC DIAGNOS 1.4 M€

INN-FLU 1.8 M€

RIVERS 1.4 M€

ConFluTech 0.5M€

“Preventing infection and spread

among humans”

• Making flu vaccines more efficient

• Understanding the biology of the

influenza virus

“Preventing infection and spread

among humans”

• Making flu vaccines more efficient

• Understanding the biology of the

influenza virus

“Early warning and strike at the

source”

• Diagnostics

• Surveillance

• Vaccination of birds

“Early warning and strike at the

source”

• Diagnostics

• Surveillance

• Vaccination of birds

13

14

15

Other Emerging Epidemics

16

Workprogramme 2007 / 2008

Emerging Epidemics

� Development of broadly protective influenzavaccine candidates – S/M CP (up to 6 million!)

� Molecular mechanisms of protection for influenza vaccines - S/M CP

� Standardisation of immunological assays for evaluation of flu vaccines in clinical trials – CSA

� Innovative point-of-care diagnostic tests for influenza – S/M CP

Workprogramme

Emerging Epidemics =

Influenza (19 April)

17

� Development of additional treatment strategiesfor Highly Pathogenic influenza – S/M CP

� Development of pandemic influenza containmentand mitigation strategies - S/M CP

� Highly innovative inter-disciplinary research on influenza – S/M CP (up to 1.5 million!)

SICA

� Influenza research with Asian partners – S/M CP

Workprogramme

Emerging Epidemics =

Influenza (19 April)

� Strengthening prediction, identification, modellingand surveillance of newly emerging infectiousdiseases in humans – L IP

� Definition of research needs and priorities in Europe in Emerging Infectious Diseases - CSA

Workprogramme

Emerging Epidemics

(18 September )

18

Option under

discussion for future

Workprogrammes

1 or 2 stage evaluation?

� Longer evaluation procedure

� Less workload for applicants – or not?

� Bottom-up topic definition…

UNITY IN DIVERSITY

19

THANK YOU FOR YOUR

ATTENTION!